Trial Profile

A Phase 3 trial evaluating effect of LB-102 in psychiatric indications

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 18 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amisulpride (Primary)
Indications Schizophrenia
Focus Therapeutic Use

Most Recent Events

14 Oct 2025 According to LB Pharmaceuticals media release, the trial is expected to initiate in 2026
31 Mar 2025 According to LB Pharmaceuticals media release, the company plans to initiate this study in Q4 2025.
22 Jan 2025 According to a Segal trials media release, LB Pharmaceuticals plans to engage with the USFDA to finalize this trial's design by early 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com